Logo image of CRDL.CA

CARDIOL THERAPEUTICS INC-A (CRDL.CA) Stock Fundamental Analysis

Canada - TSX:CRDL - CA14161Y2006 - Common Stock

1.45 CAD
-0.05 (-3.33%)
Last: 10/2/2025, 7:00:00 PM
Fundamental Rating

1

Overall CRDL gets a fundamental rating of 1 out of 10. We evaluated CRDL against 34 industry peers in the Pharmaceuticals industry. CRDL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CRDL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CRDL has reported negative net income.
CRDL had a negative operating cash flow in the past year.
CRDL had negative earnings in each of the past 5 years.
In the past 5 years CRDL always reported negative operating cash flow.
CRDL.CA Yearly Net Income VS EBIT VS OCF VS FCFCRDL.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

CRDL's Return On Assets of -140.58% is on the low side compared to the rest of the industry. CRDL is outperformed by 88.24% of its industry peers.
CRDL has a Return On Equity of -203.47%. This is amonst the worse of the industry: CRDL underperforms 85.29% of its industry peers.
Industry RankSector Rank
ROA -140.58%
ROE -203.47%
ROIC N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
CRDL.CA Yearly ROA, ROE, ROICCRDL.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

CRDL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDL.CA Yearly Profit, Operating, Gross MarginsCRDL.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, CRDL has more shares outstanding
CRDL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CRDL is higher compared to a year ago.
CRDL.CA Yearly Shares OutstandingCRDL.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRDL.CA Yearly Total Debt VS Total AssetsCRDL.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

CRDL has an Altman-Z score of -5.21. This is a bad value and indicates that CRDL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.21, CRDL is doing worse than 76.47% of the companies in the same industry.
CRDL has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
CRDL has a better Debt to Equity ratio (0.01) than 82.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -5.21
ROIC/WACCN/A
WACCN/A
CRDL.CA Yearly LT Debt VS Equity VS FCFCRDL.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

CRDL has a Current Ratio of 3.26. This indicates that CRDL is financially healthy and has no problem in meeting its short term obligations.
CRDL has a Current ratio of 3.26. This is amongst the best in the industry. CRDL outperforms 88.24% of its industry peers.
CRDL has a Quick Ratio of 3.26. This indicates that CRDL is financially healthy and has no problem in meeting its short term obligations.
CRDL's Quick ratio of 3.26 is amongst the best of the industry. CRDL outperforms 94.12% of its industry peers.
Industry RankSector Rank
Current Ratio 3.26
Quick Ratio 3.26
CRDL.CA Yearly Current Assets VS Current LiabilitesCRDL.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CRDL have decreased by -4.44% in the last year.
EPS 1Y (TTM)-4.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CRDL will show a very strong growth in Earnings Per Share. The EPS will grow by 27.45% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27%
EPS Next 2Y-5.2%
EPS Next 3Y19.5%
EPS Next 5Y27.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRDL.CA Yearly Revenue VS EstimatesCRDL.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2027 2028 2029 2030 2031 2032 100M 200M 300M
CRDL.CA Yearly EPS VS EstimatesCRDL.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRDL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRDL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDL.CA Price Earnings VS Forward Price EarningsCRDL.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDL.CA Per share dataCRDL.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as CRDL's earnings are expected to grow with 19.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.2%
EPS Next 3Y19.5%

More info and screens

0

5. Dividend

5.1 Amount

CRDL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIOL THERAPEUTICS INC-A

TSX:CRDL (10/2/2025, 7:00:00 PM)

1.45

-0.05 (-3.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12
Inst Owners8.31%
Inst Owner ChangeN/A
Ins Owners4.65%
Ins Owner ChangeN/A
Market Cap124.61M
Analysts82.5
Price Target9.95 (586.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.31%
Min EPS beat(2)29.97%
Max EPS beat(2)32.64%
EPS beat(4)3
Avg EPS beat(4)10.04%
Min EPS beat(4)-47.06%
Max EPS beat(4)32.64%
EPS beat(8)6
Avg EPS beat(8)8.61%
EPS beat(12)10
Avg EPS beat(12)13.6%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.36%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20%
EPS NY rev (1m)0%
EPS NY rev (3m)29.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.09
P/tB 7.09
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0
BVpS0.2
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -140.58%
ROE -203.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.83%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.26
Quick Ratio 3.26
Altman-Z -5.21
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)21.14%
Cap/Depr(5y)17.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y27%
EPS Next 2Y-5.2%
EPS Next 3Y19.5%
EPS Next 5Y27.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.92%
EBIT Next 3Y13.88%
EBIT Next 5Y25.19%
FCF growth 1Y10.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.12%
OCF growth 3YN/A
OCF growth 5YN/A